

10/701152

Search results

Refine Search

Your wildcard search against 10000 terms has yielded the results below.

Your result set for the last L# is incomplete.

The probable cause is use of unlimited truncation. Revise your search strategy to use limited truncation.

Search Results -

| Terms | Documents |
|---------------|-----------|
| L10 and BAC\$ | 1 |

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L12

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Sunday, December 12, 2004 [Printable Copy](#) [Create Case](#)

Set
Name Query
side by
side

Hit
Count Set
Name
result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR

| | | | |
|-----|---|-----|-----|
| L12 | L10 and BAC\$ | 1 | L12 |
| L11 | L10 and amplicon\$ | 1 | L11 |
| L10 | 6642207 [pn] | 2 | L10 |
| L9 | (artificial near chromosome\$ or YAC or BAC) near10 (herpes\$ or HSV) near10 amplicon\$ | 14 | L9 |
| L8 | L7 and amplicon\$ | 20 | L8 |
| L7 | (artificial near chromosome\$ or YAC or BAC) near10 (herpes\$ or HSV) | 69 | L7 |
| L6 | (artificial near chromosome\$ or YAC or BAC) near10 recombinant\$ near5 (viral or virus\$) near5 genome\$ | 14 | L6 |
| L5 | (artificial near chromosome\$ or YAC or BAC) near10 (viral or virus\$) near5 genome\$ | 107 | L5 |

| | | | |
|-----------|--|--------|-----------|
| <u>L4</u> | (artificial near chromosome\$ or YAC or BAC) near10 (viral or virus\$) | 2754 | <u>L4</u> |
| <u>L3</u> | (artificial near chromosome\$ or YAC\$ or BAC\$) near10 (viral or virus\$) | 4274 | <u>L3</u> |
| <u>L2</u> | artificial near chromosome\$ or YAC\$ or BAC\$ near10 (viral or virus\$) | 31330 | <u>L2</u> |
| <u>L1</u> | artificial near chromosome\$ or YAC\$ or BAC\$ | 188559 | <u>L1</u> |

END OF SEARCH HISTORY

Refine Search

Search Results -

| Terms | Documents |
|--|-----------|
| (herpes\$ or adenovir\$) near5 vector\$ near10 therapeutic and antisense\$ and ribozyme\$ and immunomodulatory | 32 |

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L10

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Sunday, December 12, 2004 [Printable Copy](#) [Create Case](#)

| Set Name | Query | Hit Count | Set Name |
|---|---|-----------|-------------------|
| <i>side by side</i> | | | <i>result set</i> |
| <i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i> | | | |
| <u>L10</u> | (herpes\$ or adenovir\$) near5 vector\$ near10 therapeutic and antisense\$ and ribozyme\$ and immunomodulatory | 32 | <u>L10</u> |
| <u>L9</u> | (herpes\$ or adenovir\$) near5 vector\$ near10 therapeutic | 727 | <u>L9</u> |
| <u>L8</u> | (herpes\$ or adenovir\$) near10 therapeutic | 1855 | <u>L8</u> |
| <u>L7</u> | L5 and immunomodulatory | 14 | <u>L7</u> |
| <u>L6</u> | L5 and immunomodulatory and cytotoxin\$ | 0 | <u>L6</u> |
| <u>L5</u> | viral near5 vector\$ near10 antisense and viral near5 vector\$ near10 ribozyme\$ | 107 | <u>L5</u> |
| <u>L4</u> | viral near5 vector\$ near10 antisense and viral near5 vector\$ near10 ribozyme\$ and viral near5 vector\$ near10 immunomodulatory | 1 | <u>L4</u> |
| <u>L3</u> | viral near5 vector\$ near10 antisense and viral near5 vector\$ near10 vaccine\$ and viral near5 vector\$ near10 ribozyme\$ and viral near5 vector\$ near10 immunomodulatory | 1 | <u>L3</u> |

| | | | |
|-----------|---|-----|-----------|
| <u>L2</u> | viral near5 vector\$ near10 antisense viral near5 vector\$ near10 vaccine\$ and viral near5 vector\$ near10 ribozyme\$ and viral near5 vector\$ near10 immunomodulatory | 797 | <u>L2</u> |
| <u>L1</u> | viral near5 vector\$ and antisense and vaccine\$ and ribozyme\$ and immunomodulatory and cytotoxin\$ | 223 | <u>L1</u> |

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 69 of 69 returned.**

-
- ☐ 1. [20040248826](#). 03 Jun 03. 09 Dec 04. Treatment of cancer by in vivo gene-transfer induced TIMP-3 expression. Auricchio, Alberto, et al. 514/44; 424/93.2 A61K048/00.
-
- ☐ 2. [20040241759](#). 17 Oct 03. 02 Dec 04. High throughput screening of libraries. Tozer, Eileen, et al. 435/7.2; G01N033/53 G01N033/567.
-
- ☐ 3. [20040229362](#). 15 May 03. 18 Nov 04. Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding genetic tools, as well as the applications of these non-pathogenic amplicon vectors. Epstein, Alberto, et al. 435/457; 435/235.1 C12N007/00 C12N015/86.
-
- ☐ 4. [20040180438](#). 28 Apr 03. 16 Sep 04. Methods and compositions for silencing genes without inducing toxicity. Pachuk, Catherine J.. 435/455; 514/44 A61K048/00 C12N015/85.
-
- ☐ 5. [20040171569](#). 04 Nov 03. 02 Sep 04. Artificial chromosome constructs containing foreign nucleic acid sequences. Horsburgh, Brian, et al. 514/44; 536/23.1 A61K048/00 C07H021/02 C07H021/04.
-
- ☐ 6. [20040166092](#). 26 Feb 04. 26 Aug 04. Use of viral vectors and charged molecules for gene therapy. Tufaro, Francis, et al. 424/93.2; 435/456 C12N015/86 C12N015/867.
-
- ☐ 7. [20040152117](#). 22 Jan 04. 05 Aug 04. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell. Giordano, Tony, et al. 435/6; C12Q001/68.
-
- ☐ 8. [20040148647](#). 26 Nov 03. 29 Jul 04. Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products. Enenkel, Barbara, et al. 800/14; 435/320.1 435/325 A01K067/027.
-
- ☐ 9. [20040105844](#). 18 Apr 03. 03 Jun 04. Method of producing herpes simplex virus amplicons, resulting amplicons, and their use. Federoff, Howard J., et al. 424/93.2; 435/5 C12Q001/70 A61K048/00.
-
- ☐ 10. [20040098755](#). 22 Jul 03. 20 May 04. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof. Mulroy, Robert, et al. 800/8; 435/252.33 435/320.1 435/325 435/6 435/69.1 530/395 536/23.5 A01K067/00 C12Q001/68 C07H021/04 C12N001/21 C07K014/47.
-
- ☐ 11. [20040029106](#). 21 Jan 03. 12 Feb 04. Duplexed parvovirus vectors. Samulski, Richard Jude, et al. 435/5; 435/235.1 435/320.1 C12Q001/70 C12N007/00.
-
- ☐ 12. [20040009604](#). 26 Mar 03. 15 Jan 04. Potent oncolytic herpes simplex virus for cancer therapy. Zhang, Xiaoliu, et al. 435/456; 435/235.1 435/320.1 530/395 C12N015/86 C12N007/00.
-
- ☐ 13. [20030232801](#). 15 Apr 03. 18 Dec 03. Identification of compounds for the treatment or prevention of proliferative diseases. Sturgess, Michael Alan, et al. 514/210.01; 514/318 514/423 514/485 514/597 546/206 548/557 548/950 552/297 A61K031/397 A61K031/445 A61K031/40 A61K031/325 C07D211/08 C07D27/08 C07D25/04 A61K031/17.

-
- ☐ 14. 20030170702. 15 Jan 03. 11 Sep 03. Methods for polysome distribution analysis of mRNA's. Hoffman, Bryan. 435/6; 435/91.2 536/25.4 C12Q001/68 C07H021/02 C12P019/34.
-
- ☐ 15. 20030165537. 30 Jan 03. 04 Sep 03. Vaccination against host cell-associated herpes viruses. Fehler, Frank, et al. 424/199.1; 424/186.1 424/204.1 424/231.1 435/320.1 435/69.1 A61K039/12 A61K039/245 C12P021/06 C12N015/00 C12N015/09 C12N015/63 C12N015/74 C12N015/70.
-
- ☐ 16. 20030097011. 25 Jun 01. 22 May 03. Novel carbamate-based cationic lipids. Schwartz, David Aaron, et al. 552/544; C07J009/00.
-
- ☐ 17. 20030095953. 12 Nov 99. 22 May 03. METHODS OF REVERSING DRUG RESISTANCE IN CANCER CELLS. CABOT, MYLES C., et al. 424/93.21; 514/44 A61K048/00.
-
- ☐ 18. 20030087807. 25 Sep 02. 08 May 03. Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity. Greenspan, Ralph J.. 514/2; 424/9.2 A61K038/00 A61K049/00.
-
- ☐ 19. 20030082723. 07 Aug 02. 01 May 03. Use of mutated recognition sequences for multiple consecutive recombinase-mediated recombinations in a genetic system. Altmann, Markus, et al. 435/69.1; 435/254.2 435/254.21 435/320.1 435/483 C12P021/02 C12N001/18 C12N015/74.
-
- ☐ 20. 20030069392. 04 Jun 02. 10 Apr 03. Cationic lipids. Lin, Kuei-Ying, et al. 530/330; 530/331 C07K005/04 C07K005/06.
-
- ☐ 21. 20030059934. 25 Mar 02. 27 Mar 03. Artificial chromosomes comprising EHV sequences. Osterrieder, Nikolaus, et al. 435/320.1; 424/199.1 424/229.1 435/235.1 435/325 435/69.1 C12P021/06 A61K039/12 A61K039/245 A61K039/255 A61K039/265 A61K039/27 C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02.
-
- ☐ 22. 20030049841. 10 Oct 01. 13 Mar 03. High throughput or capillary-based screening for a bioactivity or biomolecule. Short, Jay M., et al. 435/449; C12N015/02.
-
- ☐ 23. 20030036169. 23 Aug 02. 20 Feb 03. Methods for modulating transcriptional activation using mint proteins. Sudhof, Thomas C., et al. 435/69.1; 435/226 435/320.1 435/325 536/23.2 C12P021/02 C12N005/06 C07H021/04 C12N009/64.
-
- ☐ 24. 20030027322. 29 Nov 01. 06 Feb 03. Helper virus-free herpesvirus amplicon particles and uses thereof. Federoff, Howard J., et al. 435/235.1; 435/325 435/456 C12N007/00 C12N015/86.
-
- ☐ 25. 20020197234. 30 Jul 01. 26 Dec 02. Immunologic activities of rhesus cytomegalovirus encoded IL-10 and human cytomegalovirus encoded IL-10. Schall, Thomas J., et al. 424/85.2; 424/93.7 435/372 A61K038/20 A61K045/00 C12N005/08.
-
- ☐ 26. 20020160354. 30 Nov 98. 31 Oct 02. METHODS FOR SCREENING THERAPEUTICALLY EFFECTIVE AGENTS. CABOT, MYLES C.. 435/4; 435/7.4 C12Q001/00 G01N033/573.
-
- ☐ 27. 20020132257. 31 Jan 02. 19 Sep 02. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell. Giordano, Tony, et al. 435/6; 435/325 435/455 C12Q001/68 C12N015/87 C12N005/06.
-

-
- ☐ 28. 20020110543. 04 Jan 02. 15 Aug 02. Viral delivery system for infectious transfer of large genomic DNA inserts. Chiocca, E. Antonio, et al. 424/93.2; 435/456 A61K048/00 C12N015/869.
-
- ☐ 29. 20020102535. 11 Oct 01. 01 Aug 02. Nucleic acid molecules and polypeptides for immune modulation. McFadden, Grant, et al. 435/5; 435/219 435/41 435/6 435/7.1 530/350 530/388.3 536/23.72 C12Q001/70 C12N009/50 C07K014/065 C12Q001/68 C07H021/04 C07K014/00 C07K016/00 G01N033/53 C07K001/00 C07K017/00 C12P021/08.
-
- ☐ 30. 20020098201. 06 Dec 01. 25 Jul 02. Novel myxoma genes for immune modulation. McFadden, Grant. 424/204.1; 435/343.2 435/5 435/91.33 536/23.72 C12Q001/70 C07H021/04 C12P019/34 A61K039/12 C12N005/06 C12N005/16.
-
- ☐ 31. 20020081286. 23 May 01. 27 Jun 02. NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods. Marchionni, Mark. 424/94.1; 424/85.1 A61K038/43.
-
- ☐ 32. 20020042054. 08 Dec 00. 11 Apr 02. Vigilance nucleic acids and related diagnostic, screening and therapeutic methods. Tonomi, Giulio, et al. 435/6; 514/1 536/23.2 C12Q001/68 C07H021/04 A61K031/00.
-
- ☐ 33. 20010007656. 08 Nov 96. 12 Jul 01. TREATMENT OF DIABETES WITH TRANSCRIPTION FACTOR GENE. BOSCH, FATIMA, et al. 424/93.2; 424/450 514/44 536/23.1 A61K031/70 A01N043/04 A61K048/00.
-
- ☐ 34. 6692954. 03 Nov 00; 17 Feb 04. Generation of human cytomegalovirus yeast artificial chromosome recombinants. Ghazal; Peter, et al. 435/320.1; 435/235.1 435/255.1 435/69.1 536/23.1 536/23.72. C12N015/79.
-
- ☐ 35. 6677155. 21 Apr 00; 13 Jan 04. Triple hybrid amplicon vector systems to generate retroviral packaging lines. Sena-Esteves; Miguel, et al. 435/456; 424/93.21 435/320.1 435/325 435/457 435/69.1 514/44. C12N015/63 C12N015/00 A01N043/04 A61K031/70.
-
- ☐ 36. 6673602. 12 Jun 00; 06 Jan 04. Herpes simplex virus amplicon vector targeting system and method of using same. Spear; Matthew A., et al. 435/320.1; 424/199.1 424/205.1 424/231.1 435/5 435/69.1. C12N015/00 C12Q001/00 C12P021/06 A61K039/00 A61K039/12.
-
- ☐ 37. 6670393. 25 Jun 01; 30 Dec 03. Carbamate-based cationic lipids. Schwartz; David Aaron, et al. 514/506; 554/227 560/159. A61K031/215 C07C057/03 C07C271/06.
-
- ☐ 38. 6642207. 03 Aug 01; 04 Nov 03. Artificial chromosome constructs containing foreign nucleic acid sequences. Horsburgh; Brian, et al. 514/44; 424/93.1 424/93.2 424/93.6 435/235.1 435/320.1 435/325 435/455 435/456 435/458 435/69.1 435/91.1 435/91.4 536/23.1 536/23.72 536/24.1. A61K031/711 C12N015/86 C12N015/63 C07H021/04.
-
- ☐ 39. 6635249. 23 Apr 99; 21 Oct 03. Methods for treating congestive heart failure. Marchionni; Mark, et al. 424/145.1; 424/185.1. A61K039/395.
-
- ☐ 40. 6632934. 30 Sep 99; 14 Oct 03. MORC gene compositions and methods of use. Moreadith; Randall W., et al. 536/23.1; C07H021/04.
-
- ☐ 41. 6630589. 26 Mar 02; 07 Oct 03. Identification of compounds for the treatment or prevention of

proliferative diseases. Giordano; Anthony, et al. 546/139; 546/276.4 548/566 560/21 564/50.
C07D401/02 C07D213/02.

☐ 42. 6610664. 04 Jun 02; 26 Aug 03. Cationic lipids. Lin; Kuei-Ying, et al. 514/44; 514/397 514/399. A61K031/416 A61K031/44 A61K031/535 A61K048/00.

☐ 43. 6586184. 03 Apr 01; 01 Jul 03. Chimeric mutational vectors. Kumar; Ramesh, et al. 435/6; 435/243 435/252.1 435/252.3 435/320.1 435/440 435/471 435/485 435/488 536/22.1 536/23.1. C12Q001/68 C12N015/00 C12N015/63 C12N015/74 C12N015/70.

☐ 44. 6573090. 09 Dec 99; 03 Jun 03. Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors. Breakefield; Xandra O., et al. 435/320.1; 424/199.1 424/201.1 424/202.1 424/203.1 424/229.1 424/234.1 424/93.1 435/235.1 435/239 435/456 435/6 435/69.1 514/44 536/23.1. C12N015/81 C12N015/70 C12N015/33 C12N015/38 C12N015/869.

☐ 45. 6551575. 26 Sep 00; 22 Apr 03. Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity. Greenspan; Ralph J.. 424/9.2; 435/252.3 435/320.1 435/6 435/69.1 514/2 530/350 536/23.1. C12Q001/68 A61K049/00.

☐ 46. 6544781. 17 Jul 00; 08 Apr 03. Non-defective Epstein-Barr viral vector. Jiang; Xiaoqun, et al. 435/320.1; 435/325 435/455 514/44. C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.

☐ 47. 6440726. 24 Dec 98; 27 Aug 02. Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment. Resnick; Nitzan. 435/320.1; 435/325 435/455 435/69.1 514/44. C12N015/63 C12N015/00.

☐ 48. 6437121. 25 Apr 00; 20 Aug 02. Cationic lipids. Lin; Kuei-Ying, et al. 544/111; 544/139 544/168 548/312.7 548/338.1 564/153 564/157 564/197. C07D233/64 C07D295/104 C07D403/12 C07D413/12.

☐ 49. 6387616. 22 Dec 98; 14 May 02. Torsin, torsin genes, and methods of use. Ozelius; Laurie J., et al. 435/6; 435/91.2 536/23.1. C12Q001/68 C12P019/34 C07H021/04.

☐ 50. 6355412. 09 Jul 99; 12 Mar 02. Methods and compositions for directed cloning and subcloning using homologous recombination. Stewart; A. Francis, et al. 435/4; 435/252.1 435/252.8 435/320.1 435/325 435/6 435/91.4 536/23.1. C12Q001/00 C12Q001/68 C12N015/64 C12N015/63 C12N001/21 C12N005/10 C12N001/20 C07H021/04.

☐ 51. 6291246. 03 Nov 98; 18 Sep 01. DNA virus vectors and methods for their preparation. Delecluse; Henri-Jacques, et al. 435/477; 435/235.1 435/320.1 435/465. C12N015/74.

☐ 52. 6277621. 26 Feb 98; 21 Aug 01. Artificial chromosome constructs containing foreign nucleic acid sequences. Horsburgh; Brian, et al. 435/235.1; 435/320.1 435/325 435/366 536/23.1 536/23.2 536/23.5 536/23.51 536/23.52 536/23.72 536/24.5. C12N007/00 C12N007/01 C12N005/10 C12N015/38 C07H021/04.

☐ 53. 6261842. 13 Nov 97; 17 Jul 01. Microorganism genomics, compositions and methods related thereto. Handelsman; Jo, et al. 435/479; 435/252.3 536/23.1. C12N015/74.

- ☐ 54. 6251939. 05 Jun 96; 26 Jun 01. Carbamate-based cationic lipids. Schwartz; David Aaron, et al. 514/506; 560/159. A61K031/215 C07C271/00.
-
- ☐ 55. 6172049. 07 Jun 99; 09 Jan 01. Phosphonic acid-based cationic lipids. Dwyer; Brian Patrick, et al. 514/75; 558/166 558/177. A01N057/00 A61K031/66 C07F009/02.
-
- ☐ 56. 6171821. 14 Jun 99; 09 Jan 01. XIAP IRES and uses thereof. Korneluk; Robert G., et al. 435/69.1; 435/320.1 435/325 435/375 435/6 435/91.1 514/44 536/24.1. C12P021/06 C12P019/34 C12Q001/68 C12N015/00 A61K048/00.
-
- ☐ 57. 6093816. 27 Jun 96; 25 Jul 00. Cationic lipids. Lin; Kuei-Ying, et al. 544/122; 436/136 530/350 536/23.1 536/6.2 540/107 544/143 544/168 546/336 548/312.1 548/314.4 548/334.1 548/338.1. C07D413/02 C07D265/30 C07D295/18 A61K031/535 A61K037/7115.
-
- ☐ 58. 6093699. 10 Nov 94; 25 Jul 00. Method for gene therapy involving suppression of an immune response. Sehon; Alec, et al. 514/44; 424/178.1 424/193.1 424/280.1 424/810 424/85.1 424/93.21 435/320.1 435/455. A01N043/04 A61K031/70 C12N015/00 C12N015/63.
-
- ☐ 59. 6004804. 12 May 98; 21 Dec 99. Non-chimeric mutational vectors. Kumar; Ramesh, et al. 435/320.1; 435/456 435/463 536/23.1. C12N015/63 C12N015/00 C12N015/11.
-
- ☐ 60. 5958901. 05 Jun 96; 28 Sep 99. Phosphonic acid-based cationic lipids. Dwyer; Brian Patrick, et al. 514/75; 558/166 558/177. A61K031/665 C07F009/40.
-
- ☐ 61. 5777153. 08 Jul 94; 07 Jul 98. Cationic lipids. Lin; Kuei-Ying, et al. 560/158; 536/22.1 560/159 564/157 564/159. C07C271/20 C07C237/06 C07C237/22.
-
- ☐ 62. 5705693. 07 Jul 95; 06 Jan 98. Cationic lipids. DePrince; Randolph B., et al. 564/159; 536/22.1 560/158 560/159 564/157. C07C237/06 C07C237/22.
-
- ☐ 63. 5518913. 22 Apr 94; 21 May 96. High level recombinant protein production using conditional helper-free adenovirus vector. Massie; Bernard, et al. 435/235.1; 435/320.1. C12N007/01 C12N015/85.
-
- ☐ 64. 5384122. 22 Jul 93; 24 Jan 95. Herpesvirus particles and vaccine. Cunningham; Charles, et al. 424/231.1; 435/235.1 530/350. A61K039/12 C12N007/04 C12N015/00 C07K003/00.
-
- ☐ 65. WO002081712A2. 30 Mar 02. 17 Oct 02. ARTIFICIAL CHROMOSOMES COMPRISING EHV SEQUENCES. OSTERRIEDER, NIKOLAUS, et al. C12N015/70; C12N007/00 C12N007/04 A61K048/00 A61K039/245 C07K014/03.
-
- ☐ 66. WO002053576A1. 04 Jan 02. 11 Jul 02. VIRAL DELIVERY SYSTEM FOR INFECTIOUS TRANSFER OF LARGE GENOMIC DNA INSERTS. CHIOCCA, E ANTONIO, et al. C07H021/02; C07H021/04 C12Q001/68 A61K031/70 A01N043/04.
-
- ☐ 67. US20020110543A. Herpes simplex virus-based amplicon vector has large capacity cloning vector, herpes virus origin of replication, cleavage/packaging signal and genomic DNA fragment, and infects/delivers genomic DNA to target cell. CHIOCCA, E A, et al. A01N043/04 A61K031/70 A61K048/00 C07H021/02 C07H021/04 C12N015/869 C12Q001/68.
-
- ☐ 68. WO 200034497A. Herpes virus amplicon packaging system comprising herpes virus amplicon

vector and packaging vector having single cloning vehicle containing replication proficient but packaging defective entire herpes virus genome. ACKERMANN, M, et al. A61K039/245 A61K048/00 C12N015/33 C12N015/38 C12N015/70 C12N015/81 C12N015/869.

☐ 69. 3407257. 22 Oct 68. Combatting herpes simplex viruses with 4'-found2-nitro-1-(paratolylthio) ethyl- acetanilide. BUTHALA DARWIN A; UNDERWOOD GERALD E. 514/629; 564/218 564/219.

[Generate Collection](#)[Print](#)

| Terms | Documents |
|---|-----------|
| (artificial near chromosome\$ or YAC or BAC) near10 (herpes\$ or HSV) | 69 |

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

**PALM INTRANET**Day : Sunday
Date: 12/12/2004

Time: 17:55:31

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.

Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

tufaro

francis

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)